Log in

OTCMKTS:OPHLFOno Pharmaceutical Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: $18.00
50-Day Range
MA: $18.00
52-Week Range
Now: $18.00
Volume100 shs
Average Volume5 shs
Market Capitalization$9.25 billion
P/E Ratio19.78
Dividend YieldN/A
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for the treatment of tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for the treatment of bronchial asthma and allergic rhinitis; and Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$1.03 per share



Market Cap$9.25 billion
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive OPHLF News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLF and its competitors with MarketBeat's FREE daily newsletter.

Ono Pharmaceutical (OTCMKTS:OPHLF) Frequently Asked Questions

How has Ono Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ono Pharmaceutical's stock was trading at $22.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPHLF stock has decreased by 18.2% and is now trading at $18.00. View which stocks have been most impacted by Coronavirus.

When is Ono Pharmaceutical's next earnings date?

Ono Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Ono Pharmaceutical.

Has Ono Pharmaceutical been receiving favorable news coverage?

Media stories about OPHLF stock have trended neutral on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ono Pharmaceutical earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOno Pharmaceutical.

Who are some of Ono Pharmaceutical's key competitors?

Who are Ono Pharmaceutical's key executives?

Ono Pharmaceutical's management team includes the following people:
  • Mr. Gyo Sagara, Pres, CEO & Representative Director
  • Yukio Tani, Corp. Officer & Director of Corp. Communications
  • Mr. Hiroshi Ichikawa, Exec. Director of Sales & Marketing and Bus. Unit Director of Primary Care Bus. Unit
  • Toichi Takino Ph.D., Corp. Officer and Exec. Director of Corp. Devel. & Strategy
  • Mr. Kei Sano, Sr. Exec. Officer, Exec. Director of Corp. Mgt., Director - Product Strategy Dept. & Director

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $18.00.

How big of a company is Ono Pharmaceutical?

Ono Pharmaceutical has a market capitalization of $9.25 billion and generates $2.60 billion in revenue each year. The company earns $464.98 million in net income (profit) each year or $0.90 on an earnings per share basis. Ono Pharmaceutical employs 3,480 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The company can be reached via phone at 816-6263-5670.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.